T1	p 83 111	seasonal allergic rhinitis .
T2	p 264 300	seasonal allergic rhinitis ( SAR ) .
T3	p 504 661	Private practices and hospital clinics in Ontario , Quebec and Manitoba . POPULATION Two hundred and eighty-four out-patients with SAR , who were symptomatic
T4	p 681 715	season , volunteered for enrolment
T5	p 718 721	243
T6	p 918 922	more
T7	p 1594 1599	SAR .
T8	i 20 62	budesonide Turbuhaler with budesonide aqua
T9	i 171 181	budesonide
T10	i 297 298	)
T11	i 987 997	budesonide
T12	i 1172 1182	unpleasant
T13	i 1238 1243	spray
T14	i 1289 1299	Turbuhaler
T15	i 1307 1317	aqua spray
T16	i 1486 1508	of budesonide aqua and
T17	i 1516 1540	of budesonide Turbuhaler
T18	i 1594 1597	SAR
T19	i 1623 1652	budesonide powder formulation
T20	i 1667 1677	Turbuhaler
T21	o 83 100	seasonal allergic
T22	o 264 281	seasonal allergic
T23	o 389 404	quality of life
T24	o 745 776	Mean daily nasal symptom scores
T25	o 1026 1050	non-nasal adverse events
T26	o 1072 1085	epistaxis and
T27	o 1172 1182	unpleasant
T28	o 1202 1223	less nasal irritation
T29	o 1341 1371	Improvement in quality of life
T30	o 1553 1573	safe and efficacious